CRISPR-based assays for rapid detection of SARS-CoV-2

Vivek S. Javalkote[1], Nagesh Kancharla[1], Bhaskar Bhadra[1], Manish Shukla[1], Badrish Soni[1], Ajit Sapre[1], Michael Goodin[2*],
Anindya Bandyopadhyay[1*] and Santanu Dasgupta[1*]

[1]Reliance Industries Ltd, R&D-Synthetic Biology group, Reliance Corporate park, Navi Mumbai, India

[2]Plant Pathology Dept, University of Kentucky, Lexington, KY, USA

*Corresponding author email:
Anindya.b@ril.com,
Santanu.dasgupta@ril.com,
mgoodin.uky.edu

Keywords: SARS-CoV-2, Covid-19, CRISPR diagnostics, molecular testing, diagnostic advancements

Abstract

COVID-19 represents an unprecedented threat to global public health and economies. Assays are urgently needed for rapid detection and diagnosis of SARS-CoV-2-infected patients to inform treatment and quarantine strategies. Establishing globally accepted easy-to-access diagnostic tests is extremely important to understanding the epidemiology of the present pandemic. While nucleic acid-based tests are more sensitive with respect to serological tests, but the present gold standard RT-PCR-based assays possess limitations such as low sample throughput, requirement for sophisticated reagents and instrumentation. To overcome these shortcomings, recent efforts of incorporating LAMP-based isothermal detection, and minimizing the number of reagents required are on rise. Novel CRISPR- and other nuclease-based techniques, when merge with isothermal and allied technologies, promises to provide sensitive and rapid detection of SARS-CoV-2 nucleic acids. Here we discuss and present compilation of state-of-the-art CRISPR based detection techniques for use in COVID diagnosis and epidemiology.

Introduction:

A group of patients showing presence of pneumonia of an unknown etiology raised concern in Wuhan, China during December 2019. Sample sequencing of these patients revealed the presence of previously unknown beta-coronavirus named as 2019-nCoV later renamed as SARS-CoV-2. SARS-CoV-2 classified as clade within the subgenus sarbecovirus, Orthocoronavirinae [1,2]. Recent sequencing alignment revealed the 96% similarity between bat coronavirus and SARS-CoV-2 hypothesized bat as the most possible host of the SARS-CoV-2 before transmitted to humans. Subsequent studies show pangolins are potential intermediate host for SARS-CoV-2 virus. Highly transmissible COVID-19 virus resulted in increasing number of cases throughout the world, that leads to pandemic declaration by WHO (World Health Organization). Since the declaration of the COVID-19 pandemic on 11th of March 2020 by the WHO, more than 5.6 million people worldwide have been infected with SARS-CoV-2, resulting in more than 356254 fatalities [3]. An accurate view of the epidemiology of this disease requires rapid testing and identification to inform followed by contract tracing and quarantine strategies necessary to slow the rate of transmission [4]. Complicating the epidemiology of COVID-19 is the finding that asymptomatic carriers are able to shed/transmit SARS-CoV-2 prior to onset of symptoms [5].

At present, two general types of tests are available for COVID19, namely, serological tests and nucleic acid-based tests. While serological detection has the advantages of being easier to conduct, without need for sophisticated instruments, these tests depend on antibody detection, which requires seroconversion to occur in patients prior to administration of the test. During the incubation period of 5-14 days prior to symptom onset, serological tests may suffer from a high rate of false-negative reporting due to low titer of IgM or IgG antibodies in blood samples [6].

In contrast, nucleic acid-based tests are confirmatory and so far, qRT-PCR is gold standard. qRT-PCR involves RNA isolation from patient sample (nasal, nasopharyngeal or oropharyngeal swabs, sputum, lower respiratory tract aspirates) and cDNA synthesis followed by amplification of target regions of viral genome detected using double strand specific SYBR green or TaqMan-based fluorescent probes (Fig. 1) [7]. Usually N/Nucleocapsid gene, ORF1b, RDRP and E gene of the COVID 19 virus is amplified for detection (Table-1). Multiplexing i.e. amplification of part of two or more genes at a time is also possible in this technique for further confirmatory detection.

There are several drawbacks to qRT-PCR-based tests, such as the requirement for a centralized laboratory, trained technical staff, sophisticated instrumentation, and expensive reagents that may not be available at the point of care. Additionally, the overall turnaround time may be quite long. Although detection assays themselves may only require 3-4 hours, collection, transport, and data analyses may extend reporting to greater than 24 hours.

The other promising nucleic acid based test is LAMP (Loop-mediated isothermal amplification) and its refined version known as RPA (Recombinase Polymerase amplification) [8,9]. Both methods are alternatives to RT PCR. Since these are isothermal amplification techniques, a simple heating block can replace expensive thermocycler machines. Elimination of thermocycling helps in reduction of overall time needed for the tests and reduces the cost per assay.

Fig. 1. Flow diagram demonstrating steps of qRT PCR based detection of viral nucleic acid in sample. a) Nasopharyngeal swab collection from infected patients b) RNAs extracted from samples (red strand) c) Reverse transcription for cDNA synthesis (green strand) and amplification (RT-PCR) conducted by using target specific primers (eg. SARS-CoV-2 N gene or RDRP gene) d) Quantitative real time PCR (qRT-PCR) conducted to identify positive samples. Amplification of sample monitored in real time based on fluorescence generated by incorporation of dyes like SYBR green in double stranded DNA. Further TaqMan probes specific to target sequence increases the specificity and sensitivity.

The LAMP technique involves targeting of 6 target sequences with 4 primers along with application of a strand-displacing DNA polymerase. Targeting of several sequences simultaneously makes the assay highly selective for SARS-CoV-2. The reaction endpoint can be determined using double-stranded DNA binding dyes or colorimetric pH indicator dyes (Fig-2). Alternatively, RPA utilizes the key enzymes like recombinase, single stranded DNA-binding protein (SSB) and strand displacing polymerase. The reaction starts with pairing of primer to double-stranded DNA by displacing one strand with the help of recombinase enzyme. Single-stranded DNA stabilized by SSB proteins and then amplification of DNA is carried out by a strand-displacing polymerase akin to PCR amplification. To detect RNA targets, amplification occurs after reverse transcription. The advantage of RPA is its optimal temperature ranges between 37°C to 42°C, which allows it to be conducted in simple water bath. Within 10 min, few viral copies could be converted into detectable amount. Further addition of exonuclease III leads to generation of signal by cleavage of exo-probe functioning as real time PCR [8].

Although Isothermal reactions promises cheaper and easier alternative to RT-PCR but optimization of primers and reaction parameters still an issue. Therefore, sensitivity and accuracy are challenging for isothermal techniques.

Coupling isothermal reactions with CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) based nucleases found to be an advanced effective tool for nucleic acid-based detection.

CRISPR based methods for detection of virus and pathogens:

Discovery of CRISPR mediated adaptive immunity and a range of CRISPR-associated proteins (Cas) has not only led transformative advances in genome editing but also in the space of developing next-gen nucleic acid-based diagnostics of disease and pathogen. Integration of lateral-flow chemistry in CRISPR diagnostics opened windows of opportunities for towards development of rapid, reliable, specific, and cheap diagnostic kits. CRISPR system has been used for development of molecular diagnostics kits for detection of Dengue virus (DENV), human papillomavirus (HPV) and Zika virus (ZIKV) in human samples [19].

Fig. 2. Schematic representations of LAMP for detection of viruses in samples. a) Sample (Nasopharyngeal swab) collection b) RNA extracted from samples (green strand) c) Reverse transcription for cDNA synthesis (red strand) and amplification by strand displacement reaction proceeds at a constant temperature. d)-g) Shows LAMP reaction: Target sequence is amplified using four sets of primers with a highly efficient polymerase. Four primer used are specific to target regions involves Forward Inner Primer (FIP), Forward Outer Primer (FOP), Backward Inner Primer (BIP) and Backward Outer Primer (BOP). FOP amplifies the one strand of DNA and displaces the other strand e) Displaced strand forms loop and serves as a template for BIP and complementary strand is formed f) BOP amplifies the complementary strand and form a dumbbell shape structure g) Amplification is achieved by repeating the extensions by respective primers h) Amplified nucleic acids further can be detected by qRT-PCR or paper strip based detection methods (Amplification also observed in real time by using pH sensitive dyes in reaction mixture and monitoring the color change. Due to accumulation of H⁺ ions in the reaction mixture, which leads to increased pH)

Fig. 3. Fundamental steps of various CRISPR based covid-19 detection tests. (A) Shows collection of samples, transport in viral transport medium and isolation of RNA (B) Conversion of RNA to cDNA by Reverse transcription. This amplification step could be conducted at isothermal conditions by following RT-RPA of RT-LAMP method. (C) Amplified nucleic acid of viral sample need to be identified by specific viral gene amplification. Conventional method (qRT PCR) utilizes viral gene specific primers to amplify the specific gene segment and further these segments detected by double strand intercalating SYBR dye or fluorescent probes. Recent advancements in CRISPR based diagnostics (CRISPR-Dx) enabled utilization of different Cas enzymes for detection with high sensitivity either from RNA (Cas-13 based detection) or from cDNA (Cas12, Cas9 based etc.) followed by color reaction due to the cleavage of reporter probes by the activated Cas enzymes.

In 2018, Feng Zhang and team developed a method for multiplexed and portable nucleic acid detection platform which used Cas13, Cas12a, and Csm6, called SHERLOCK (specific high-sensitivity enzymatic reporter unlocking) [20] and have successfully used the system for detection of human viruses. In addition to SHERLOCK, there are other CRISPR – based detection techniques published recently (Table-1). One of such techniques is DECTECTR, developed by Mammoth Bioscience. DECTECTR is Cas12a based detection method that involves Cas12a activation after binding with COVID-cDNA and cuts reporter probes (oligonucleotide sequences labelled with the reporter molecules 6-carboxyfluorescein (FAM) and biotin) which confirms detection of virus. Similarly, another Cas12a-based technique CASdetect has been successfully developed, where gRNA has been modified to improve the accuracy further.DECTECTR AND CASdetec were reported to detect the viral RNA genome samples at a level of $10^4 – 10^5$ copies per ml of sample [21]. In addition to SARS-CoV-2 CASdetect has been successfully used for detection of other

coronaviruses (SARS-CoV, MERS-CoV, CoV-HKU1, CoV-229E, CoV-OC43, and CoV-NL63) known to cause respiratory diseases with high sensitivity and specificity [21]. Other CRISPR- assisted nucleases such as fnCAS9, Cas12b have also been used for COVID-19 detection, and of these fnCAS9 with its higher mismatch specificity exhibited very high level of accuracy for faster detection [21,22]. Table 3 shows genes of Covid-19 amplified during different CRISPR-based detection assays. Recently, Sherlock Biosciences (Cambridge, USA), received approval from US Food and Drug Administration's (FDA) for employing CRISPR-based diagnostic kit for screening COVID-19 cases. The company is working on programming the CRISPR machinery, which could extract SARS-CoV-2 genetic material in a swab samples from taken from nose, mouth or throat of patients, or in fluid from the lungs [5].

CRISPR-Cas13a (C2C2) enzyme based Covid-19 detection:

Gootenberg *et al.* utilized the Cas13a instead of Cas9 considering its ability to bind and cleave RNA rather than DNA substrate [26]. This potential leverage this method to be utilized for viral RNA detection directly. Further contrasting to Cas9, Cas13a becomes an enzymatically active entity instead of returning to inactive state. Active Cas13a cleaves surrounding RNAs regardless of homology. Additionally, this group of scientists developed a technology which provides potential of detection rapidly with high sensitivity, single base specificity and all this on a portable platform. This technology called as SHERLOCK (Specific High-sensitivity Enzymatic Reporter un-LOCKing). which utilizes the recombinase polymerase amplification (RPA) as it an isothermal nucleic acid amplification substitutes need of sophisticated PCR machine. SHERLOCK directly works on RNA virus detection and could also be useful in DNA detection by incorporating reverse transcriptase in reaction to convert DNA to RNA. Amplified RNA molecules are subjected to Cas13a nuclease with a guide RNA specific to sequence of interest. After binding to complementary sequence of guide RNA to sample RNA, Cas13a get activated. Active Cas13a shows nonspecific collateral cleavage activity. This collateral cleavage activity reports the signal by cleavage of short nucleotide sequence that is coupled to a fluorescent reporter and a quencher. Cas13a proved its ability to detect RNA as low as 2% of total serum in reactions. There was confirmed differentiation

between Zika virus (ZIKV) and dengue virus (DENV) at minimum concentration of 2000 copies of viral genome per mL (3.2aM) [26]. Further scientist group of Myhrvold *et al* introduced HUDSON technique, to introduce simplicity and convenience in RNA extraction from various samples [27]. HUDSON is a method of RNA extraction by lysis of viral particles with inactivation of RNases found in body fluids by using heat and chemical reduction. Advantage of using HUDSON extraction is, the samples after RNA extraction could be directly added to RPA reactions without dilution or purification (to avoid solidification during heating, blood products diluted 1:3). HUDSON combined with SHERLOCK enables detection from range of samples (urine, whole blood, plasma, serum, or saliva) with sensitivity [27]. In the most recent version of the SHERLOCK technique (SHERLOCKv2**)** (Fig. 4)**.** Gootenberg *et al* achieved four-channel multiplexing with 3.5 times increased signal sensitivity to measure as low as 2 aM concentration (2 x 10^{-18} molar viral RNA). They also discussed application of lateral flow strip based detection by using FAM-RNA-Biotin reporter. They reported use of HybriDetect strips from Milenia as strip based convenient assay. Addition of CRISPR type-III effector nuclease Csm6 to this reaction utilized for amplified signal detection. Property of synergistic activation of Csm6 by Cas13 leads to enhancement of signal [20].

CRISPR-Cas12a (Cpf1) enzyme for detection:

The Doudna group at the University of California Berkley utilized Cas12a in a CRISPR-based detection assay, DNA Endonuclease Targeted CRISPR Trans Reporter (DETECTR). Chen et al. reported remarkable phenomenon about Cas12a. When target sequence complementing at least 15 nucleotides of crRNA, Cas12a cleaves double stranded DNA and get activated. Activated Cas12a shows trans-ssDNA collateral cleavage activity and cleaves single stranded DNA without any specificity known as indiscriminate single-stranded DNase activity [28]. Mammoth

Biosciences Inc. (San Francisco, California, USA) has reconfigured the DETECTR platform for the detection of SARS-CoV-2 within 30 min time from sample to read-out by using lateral flow strip format [5]. RNAs extracted from sample simultaneously subjected to reverse transcription and isothermal amplification by using loop-mediated amplification (RT-LAMP). RT-LAMP reaction takes 20 min and conducted at 62°C. Further Cas12a binds specifically predefined SARS-CoV-2 gene sequences and get activated. This activated Cas12a cleaves the reporter probes which in term serves readout in lateral flow strip detection (Fig. 5). Cas12a can perform 88 detections in 10 min at 37°C within 10 minutes [5].

Table1. Different non-CRISPR methods for detection COVID19

Test	Description	References
Serological immunoassays	1) Rapid diagnostic test (RDT) (detection in 10 to 30 min) 2) Enzyme linked immunosorbent assay (ELISA) (detection in 1 to 5 hrs) 3) Neutralization assay (detection in 3 to 5 days).	[6,10]
Real time RT-PCR	Real time RT-PCR detection is more sensitive and advantageous over reverse transcriptase (RT-PCR)	[11,12]
Super high-speed qRT-PCR (SHRT-PCR)	Special rotating disk used for rotating samples to different set temperatures specific to each step of PCR, reducing the time required for temperature ramp up and ramp down time	[13]
TaqMan-based RT-PCR	TaqMan probes improve the sensitivity of assays	[11,14]
Dual TaqMan probe-based RT-PCR	2 probes specific for different sequences used for reducing the detection time with ultra-sensitivity	[15]
Multiplex RT-PCR	Four mismatch-tolerant molecular beacons targeting four gene used for detection to overcome the issue of rapid mutation in sequences	[11,16]
RT-LAMP	Reverse transcription followed by as loop-mediated isothermal amplification. Abolishes the need of sophisticated instruments like thermal cycler as reaction is possible at single temperature by using water bath.	[8,17]
RT-RPA	Reverse transcription followed by Recombinase polymerase amplification (RPA) which is also an isothermal amplification	[9]
Microarray based detection	Complementary probes coated on wells of plate utilized for detection	[18]

Table 2. CRISPR based diagnostics for COVID 19

Cas 13a	Cas12a	Cas12b	fnCan9
Sherlock	DETECTOR	CasDETECT	FELUDA
HUDSON	AIOD		
Sherlock 2.0	ENHANCE		

All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay:

Ding et al. utilized two individual crRNAs to generate pair of Cas12a-crRNA which binds to two different sites of target sequence near to RPA primer binding sites [24]. At 37°C RPA amplification initiates first, and

displacement of strands exposes the Cas12a-crRNA binding sites of target sequence. Binding of Cas12a-crRNA on target site activates its endonuclease activity which cleaves the ssDNA-FQ reporter (single stranded DNA sequences labelled with the reporter molecules 6-carboxyfluorescein (FAM) and quencher) to produce fluorescence. This same process repeated continuously on amplified products of RPA. This is gives leverage to amplify the signal of detection. Once the complementary sequence binding happens in positive samples, Cas12a cleaves other ssDNA-FQ reporters in proximity by indiscriminate single-stranded DNase activity producing. This all process is possible in single tube gives advantage by eliminating need of separate preamplification and amplified product transferring. Further the detection is possible by naked eyes. They also reported that there was no significant difference in positive and negative sample fluorescence when the tubes are kept at room temperature even after 10 min. At 37°C within one minute there was notable difference in fluorescence of positive sample give further advantage to control the reaction at temperature (Fig. 6) [24].

Enhanced analysis of nucleic acids with crRNA extensions (CRISPR-ENHANCE):

In this technique optimization of CRISPR-based detection assay was achieved. This technique relies on earlier observations about improvement of Cas12a activity due to extended secondary DNA on the guide crRNA or a hairpin RNA structure added to the sgRNA or chemically modified Cas12a guided RNA. Nguyen et al. developed the CRISPR-ENHANCE (**Enh**anced **a**nalysis of **n**ucleic acids with crRNA **e**xtensions) technique by using engineered crRNA+3'DNA7 [25]. Observations also revealed that normal system detects RNA efficiently only when target strand for crRNA is DNA rather than RNA in a heteroduplex. But crRNA+3'DNA7 is more efficient in enzymatic collateral activity on DNA/RNA heteroduplex compared to wild type crRNA. For detection of SARS-CoV-2 crRNAs were designed to target nucleocapsid phosphoprotein encoding N gene. Engineered crRNA+3'DNA7 proved higher sensitivity than wild type crRNA of SARS-CoV-2 for detection within 30 minutes. Integration of paper based lateral flow assay with FITC-ssDNA-Biotin reporter reduced detection time to 20 min and detection of SARS-CoV-2 cDNA to 1 nM without any target amplification. Reverse transcription along with loop mediated isothermal amplification (RT-LAMP) when used the detection limit further reduced to 3-300 copies of RNA by wild type crRNA as well as engineered crRNA+3'DNA7. But wild type crRNA showed more darker control band (due to insufficient cutting of reporter probes) compared to engineered crRNA+3'DNA7 on paper strip (due to more efficient cutting of reporter probes). When band intensity compared, ENHANCE showed average 23-fold intensity ratio of positive band to control band compared to wild type crRNA's average 7-fold ratio at SARS-CoV-2 RNA concentration between 1 nM and 1 pM. Also, in case of ENHANCE visible confirmation was started to get achieved sooner i.e. within 30 seconds. Thus, in this technique optimization of CRISPR-based detection assay was achieved (Fig. 7) [25].

Table 4. Showing different CRISPR based techniques and subsequent virus (Covid-19) gene targets. *NA: Not applicable, **N gene: nucleocapsid protein, S gene: spike protein, Orf1ab gene: replicase polyprotein, E gene: envelope protein, RdRp: RNA dependent RNA polymerase, NSP8: non-structural protein 8.

Test	sgRNA designing target sequence**	Cas	Reference
qRT-PCR	SARS-CoV-2 N gene, RdRP gene, & E gene	NA*	[7]
SHERLOCK	SARS-CoV-2 S gene & Orf1ab gene	Cas13a	[23]
DETECTR	SARS-CoV-2 N gene & E gene	Cas12a	[5]
AIOD-CRISPR	SARS-CoV-2 N gene	Cas12a	[24]
ENHANCE	SARS-CoV-2 N gene	Cas12a	[25]
CASdetec	SARS-CoV-2 RdRp gene	Cas12b	[21]
FELUDA	SARS-CoV-2 NSP8 and N gene	Cas9	[22]

CRISPR-Cas12b-mediated DNA detection (CASdetec):

CASdetec technique evolved by combining sample treatment protocol with amplification methods and detection of viral nucleic acid by CDetection, which is Cas12a enzyme based. For extraction of viral genome two methods were tested i.e. 1) virus genome extraction kits (spin column) and 2) lysis buffer. Out of which spin column method provide lower detection limit of 10 copies/µL of viral genome but lysis buffer offers convenience at point-of-care testing (POCT). It was observed that 3-fold increase in sgRNA concentration enhances the rate of reaction along with improved fluorescence signal and less background noise by increasing molecular collision between CRISPR and target sequence. For further increment in fluorescence signal incorporation of poly-T fluorescence-quenchers

Fig. 4. Schematic representation of Specific High-sensitivity Enzymatic Reporter un-LOCKing (SHERLOCK). a) Sample collection (nasopharyngeal swabs) b) RNA extracted from samples by using HUDSON method (red strand) c) RNA amplification by using Recombinase Polymerase amplification (RT-RPA) and T7 polymerase under isothermal conditions (green strand) d) Cas13a CRISPR ribonucleoprotein (RNP) complex with target specific crRNA added to amplified samples e) RNP complex get activated due to binding with target RNA sequence of positive samples and cleaves the ssRNA reporter probe (Fluorophore FAM with biotin at respective ends) f) Lateral flow strip based detection. Cleaved FAM bearing part of reporter probe present only in positive samples gets accumulated at test band (T) and further get visible due to gold nanoparticle conjugated anti-FAM antibody accumulation. Uncut reporters get accumulated at control band (C).


Fig. 5. Schematic representation of DNA Endonuclease Targeted CRISPR Trans Reporter (DTECTR). a) Sample collection (nasopharyngeal swab) b) RNA extracted from sample c) Reverse transcription for cDNA synthesis and amplification by using Loop mediated isothermal amplification (RT-LAMP) at 62°C for 20 min. (green strands with yellow loops) d) Target specific crRNA CRISPR ribonucleoprotein (RNP) complex mixed with amplified products e) Cas12a of RNP complex get activated after binding with target sequences present in positive samples and cleaves ssDNA reporter probes (FAM and biotin at respective ends) f) Lateral flow strip based detection: Cleaved FAM bearing part of reporter probe present only in the positive samples get accumulated at test band and further get visible due to gold nanoparticle conjugated anti-FITC antibody accumulation.


Fig. 6. Figure elucidating AIOD-CRISPR assay. a) Sample collection (nasopharyngeal swab) b) RNA extracted from sample (c) Reverse transcription for cDNA synthesis and amplification by using Recombinase Polymerase amplification (RT-RPA) at 37°C all in one incubation in single tube d) Cas12a CRISPR ribonucleoprotein (RNP) complex with distinct forward and reverse crRNAs added to amplified samples e) RNP complex get activated due to binding with target sequence of positive samples and cleaves the ssDNA-FQ reporter probe (Fluorophore FAM with quencher molecule) f) Due to cleavage of reporter probe quencher and fluorophore get separated and fluorescence could be detected under blue or UV light in positive samples after 40 min in same single tube.

were used. More specifically 7 nucleotide length poly-T reporter was utilized which provided highest signal in shortest time along with sgRNA around RdRp locus. Considering the average viral load representing less than 1 to about 1000 copies per microliter of RNA efficient amplification method is needed. Recombinase-aided amplification (RAA) was used to amplify the substrate 10^{10} times (from aM to 10 nM) within 10-30 minutes at constant temperature between 37°C to 42°C. It is better to perform amplification RT-RAA and CDetection of viral nucleic acid in single tube, to prevent aerosol contamination chances which is possible when that sample is exposed to environment during testing steps. But when both reactions

Fig. 7. Diagrammatic representation of CRISPR-ENHANCE assay. A] Steps of ENHANCE assay a) Samples like nasopharyngeal swabs collected b) RNAs extracted from samples (red strand) c) Reverse transcription for cDNA synthesis and amplification by using Loop mediated isothermal amplification (RT-LAMP) at 62°C for 20 min (green strands with yellow loops) d) Engineered crRNAs Cas12a RNPs mixed with amplified products e) Cas12a of RNP complex get activated after binding with target sequences present in positive samples and cleaves ssDNA reporter probes (FITC and biotin at respective ends) f) Lateral flow strip based detection: Cleaved FITC bearing part of reporter probe present only in positive samples get accumulated at test band and further get visible due to gold nanoparticle conjugated anti-FITC antibody accumulation. . B] Engineered crRNA Cas12a RNPs developed by i) extended secondary DNA on the guide crRNA or ii) a hairpin RNA structure added to the sgRNA or iii) chemically modified Cas12a guided RNA

Fig. 8. Diagrammatic representation of the CasDETEC assay. a) Sample collection (nasopharyngeal swab) b) RNA extracted from samples by using spin column-based kit or lysis buffer c) Reverse transcription for cDNA synthesis and amplification by using recombinase aided amplification (RT-RAA) at 42°C for 30 min (green strands) d) Cas12b CRISPR ribonucleoprotein (RNP) complex stored in lid of tube mixed after amplification e) RNP complex get activated due to binding with target sequence of positive samples and cleaves the ssDNA-FQ 7nt poly-T reporter probe (Fluorophore with quencher molecule) f) Due to cleavage of reporter probe quencher and fluorophore get separated and fluorescence could be detected under blue or UV light in positive samples.

conducted in single tube it drastically reduces the sensitivity. To overcome this issue, Guo et al. executed RT-RAA reaction within the tube and CDetection reagents were kept in the lid of the tube [21]. Then after amplification the reagents present in lid were spun down into the tube for detection. Sigle tube operations solved the problem of false positive results due to contamination during transfer and exposure to environment aerosols. To make detection more convenient for POCT, they designed portable dark box fitted with blue LED. Blue LED exposure generates visual confirmation of positive samples in single tube itself (Fig. 8). Report suggest detection limit as low as 10 copies/µL without cross contamination [21].

CRISPR-Cas9 enzyme based detection technique:

Cas9 enzyme is one of the ubiquitously used enzyme for genetic editing [29]. Cas9 bind specifically to a DNA sequence complementary to guide RNA and serves the endonuclease activity at target site. In case of utilization of this enzyme in CRISPRDx, Azhar et al. reported FnCas9 Editor Linked Uniform Detection Assay (FELUDA) [22]. Cas9 ortholog from *Francisella novicida* named as FnCas9 used in this assay as it shows high mismatch sensitivity. FnCas9 do not bind to a sequence which harbor mismatch. RNA from viral samples amplified by using biotinylated primers using

Fig. 9 Schematic representation of paper strip based FnCas9 Editor Linked Uniform Detection Assay (FELUDA). a) Sample (Nasopharyngeal swab) collection b) RNAs extracted from samples c) Reverse transcription for cDNA synthesis and amplification by using biotin labelled primers (green strand) d) FAM labelled an active CRISPR ribonucleoprotein (RNP) complex (FAM labelled tracrRNA is compatible with multiple crRNAs) showing no mismatch in sgRNA and target sequences of positive samples e) RNP complex get activated due to binding with target sequence of positive samples and cleaves the FAM labelled tracrRNA f) Lateral flow strip based detection. FAM labelled RNP bound to biotinylated target sequence of positive samples get accumulated at streptavidin test Band and further get visible due to gold nanoparticle conjugated anti-FAM antibody accumulation.


Fig .10. Workflow comparison of CRISPR based detection of SARS-CoV-2

Recombinase Polymerase Amplification (RPA) method. RPA provides advantage of conducting this technique at isothermal conditions which crucial for point-of-care (POC) where sophisticated setup is not available. CRISPR ribonucleoprotein (RNP) FnCas9 complex labelled with FAM and the biotin labelled amplicons are utilized for detection by using commercially available paper strips. Test line of strip is populated with streptavidin. The biotin labeled amplicons specific to SARS-CoV-2 going to bind at test line along with FAM labelled RNP, subsequently bind to anti-FAM antibody linked gold nanoparticles flow through applied buffer. In absence of biotin labelled amplicons in the sample, the FAM labelled RNP will not bind at streptavidin test band line,. Anti-Rabbit antibody is coated at control line, where unbound gold nanoparticle conjugated anti-FAM antibody get bind and shows color band (Fig. 9) [14].

Summary:

Point of care, easy to perform tests are extremely important for diagnosis of Covid19, as laboratory facilities may not be accessible in poor countries or even places of greater risk of infection such as airports, ports, emergency departments etc. Instrument free, field deployable test kits with higher accuracy and specificity would be ideal for containment of such disease. CRISPR based diagnosis tools promises such accuracy and much shorter turnaround time vis-à-vis other nucleic acid-based methods.

While sherlock provides a quick diagnostic with the help of CRISPR-Cas13a based reporter targeting and recently got approval from CDC USA, other modified version of sherlock such as HUDSON or Sherlock 2.0 aids in simpler RNA extraction / extraction from body fluid directly and higher signal detection respectively. Mammoth bioscience's DETECTOR technique exploits genome editing capability of Cas12a and its simultaneous single stranded DNA targeting while activated. Dual AIDO CRISPR system further simplifies Cas12a based detection by offering single tube reaction and fluorescence based detection without use of strips. Similarly, CRISPR ENHANCE improves Cas12a based detection even in a femtomolar range of viral nucleic acid by modifying/improving crRNA and other parameters. CDetection platform of Guo et al exploits editing capability of Cas12b (C2C1) and provides another option for using class-2-V CRISPR system. So far only one report is there for the most popular DNA targeting Class 2, CRISPR Nuclease Cas9, which is FELUDA technology based on dead Fn Cas9 and detects cDNA of viral origin by enzymatic readout, without editing any separate reporter molecule. Fig.9. shows a comparative analysis of workflow of different CRISPR based systems and total time needed to perform the tests. We believe that with this continuing effort of developing diverse testing methods using CRISPR system further advances the faster Covid-19 detection at the point of care.

References

1. Rothan, H.A.; Byrareddy, S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J. Autoimmun.* **2020**, *109*, 102433, doi:10.1016/j.jaut.2020.102433.
2. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* **2020**, *382*, 727–733, doi:10.1056/NEJMoa2001017.
3. Who.int Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed on May 29, 2020).
4. Wilder-Smith, A.; Freedman, D.O. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. *J. Travel Med.* **2020**, *27*, 1–4, doi:10.1093/jtm/taaa020.
5. Broughton, J.P.; Deng, X.; Yu, G.; Fasching, C.L.; Singh, J.; Streithorst, J.; Granados, A.; Sotomayor-Gonzalez, A.; Zorn, K.; Gopez, A.; et al. Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. *medRxiv.* **2020**, 2020.03.06.20032334, doi:10.1101/2020.03.06.20032334.
6. Bruning, A.H.L.; Leeflang, M.M.G.; Vos, J.M.B.W.; Spijker, R.; De Jong, M.D.; Wolthers, K.C.; Pajkrt, D. Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: A systematic review and meta-Analysis. *Clin. Infect. Dis.* **2017**, *65*, 1026–1032, doi:10.1093/cid/cix461.
7. Corman, V.M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D.K.; Bleicker, T.; Brünink, S.; Schneider, J.; Luisa Schmidt, M.; et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* **2019**, *3*, 1–8, doi:10.2807/1560-7917.ES.2020.25.3.2000045.
8. Thi, H.; Thai, C.; Le, M.Q.; Vuong, C.D.; Parida, M.; Minekawa, H.; Notomi, T.; Hasebe, F. Development and Evaluation of a Novel Loop-Mediated Isothermal Amplification Method for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus Development and Evaluation of a Novel Loop-Mediated Isothermal Amplification Method for Rapid Detectio. *J. Clin. Microbiol.* **2004**, *42*, 1956–1961, doi:10.1128/JCM.42.5.1956.
9. Aebischer, A.; Wernike, K.; Hoffmann, B.; Beer, M. Rapid genome detection of Schmallenberg virus and bovine viral diarrhea virus by use of isothermal amplification methods and high-speed real-time reverse transcriptase PCR. *J. Clin. Microbiol.* **2014**, *52*, 1883–1892, doi:10.1128/JCM.00167-14.
10. Ben-Selma, W.; Harizi, H.; Boukadida, J. Immunochromatographic IgG/IgM test for rapid diagnosis of active tuberculosis. *Clin. Vaccine Immunol.* **2011**, *18*, 2090–2094, doi:10.1128/CVI.05166-11.
11. Hadjinicolaou, A. V.; Farcas, G.A.; Demetriou, V.L.; Mazzulli, T.; Poutanen, S.M.; Willey, B.M.; Low, D.E.; Butany, J.; Asa, S.L.; Kain, K.C.; et al. Development of a molecular-beacon-based multi-allelic real-time RT-PCR assay for the detection of human coronavirus causing severe acute respiratory syndrome (SARS-CoV): A general methodology for detecting rapidly mutating viruses. *Arch. Virol.* **2011**, *156*, 671–680, doi:10.1007/s00705-010-0906-7.
12. Noh, J.Y.; Yoon, S.W.; Kim, D.J.; Lee, M.S.; Kim, J.H.; Na, W.; Song, D.; Jeong, D.G.; Kim, H.K. Simultaneous detection of severe acute respiratory syndrome, Middle East respiratory syndrome, and related bat coronaviruses by real-time reverse transcription PCR. *Arch. Virol.* **2017**, *162*, 1617–1623, doi:10.1007/s00705-017-3281-9.
13. Sakurai, A.; Nomura, N.; Nanba, R.; Sinkai, T.; Iwaki, T.; Obayashi, T.; Hashimoto, K.; Hasegawa, M.; Sakoda, Y.; Naito, A.; et al. Rapid typing of influenza viruses using super high-speed quantitative real-time PCR. *J. Virol. Methods.* **2011**, *178*, 75–81, doi:10.1016/j.jviromet.2011.08.015.
14. Wu, Q.; Xu, Z.; Wei, T.; Zeng, H.; Li, J.; Gang, H.; Sun, M.; Jiang, F.; Wang, X.; Dong, W.; et al. Development of Taqman RT-nested PCR system for clinical SARS-CoV detection. *J. Virol. Methods.* **2004**, *119*, 17–23, doi:10.1016/j.jviromet.2004.02.011.
15. SP Yip, SST To, PH Leung, TS Cheung, PK Cheng, W.L. Use of Dual TaqMan Probes to Increase the Sensitivity of 1-Step Quantitative Reverse Transcription-PCR: Ap- plication to the Detection of SARS Coronavirus. *Clin. Chem.* **2005**, *51*, 1885–1888, doi:10.1373/clinchem.2005.054106.
16. Yu, X.F.; Pan, J.C.; Ye, R.; Xiang, H.Q.; Kou, Y.; Huang, Z.C. Preparation of armored RNA as a control for multiplex real-time reverse transcription-PCR detection of influenza virus and severe acute respiratory syndrome coronavirus. *J. Clin. Microbiol.* **2008**, *46*, 837–841, doi:10.1128/JCM.01904-07.
17. Silva, S.J.R. da; Paiva, M.H.S.; Guedes, D.R.D.; Krokovsky, L.; Melo, F.L. de; Silva, M.A.L. da; Silva, A. da; Ayres, C.F.J.; Pena, L.J. Development and Validation of Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) for Rapid Detection of ZIKV in

----

Mosquito Samples from Brazil. *Sci. Rep.* **2019**, *9*, 1–12, doi:10.1038/s41598-019-40960-5.

18. Hardick, J.; Metzgar, D.; Risen, L.; Myers, C.; Balansay, M.; Malcom, T.; Rothman, R.; Gaydos, C. Initial performance evaluation of a spotted array Mobile Analysis Platform (MAP) for the detection of influenza A/B, RSV, and MERS coronavirus. *Diagn. Microbiol. Infect. Dis.* **2018**, *91*, 245–247, doi:10.1016/j.diagmicrobio.2018.02.011.

19. Chertow, D.S. Next-generation diagnostics with CRISPR. *Science.* **2018**, *360*, 381–382, doi:10.1126/science.aat4982.

20. Gootenberg, J.S.; Abudayyeh, O.O.; Kellner, M.J.; Joung, J.; Collins, J.J.; Zhang, F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. *Science.* **2018**, *360*, 439–444, doi:10.1126/science.aaq0179.

21. Lu Guo, Xuehan Sun, Xinge Wang, Chen Liang, Haiping Jiang, Qingqin Gao, Moyu Dai, Bin Qu, Sen Fang, Yihuan Mao, Yangcan Chen, Guihai Feng, Qi Gu, Liu Wang, Ruiqi Rachel Wang, Qi Zhou, W.L. SARS-CoV-2 detection with CRISPR diagnostics. *bioRxiv.* **2020**, doi:10.1101/2020.04.10.023358.

22. Mohd. Azhar, Rhythm Phutela, Asgar Hussain Ansari, Dipanjali Sinha, Namrata Sharma, Manoj Kumar, Meghali Aich, Saumya Sharma, Khushboo Singhal, Harsha Lad, Pradeep K. Patra, Govind Makharia, Giriraj Ratan Chandak, Debojyoti Chakraborty, S.M. Rapid, field-deployable nucleobase detection and identification using FnCas9. *bioRxiv.* **2020**, doi:10.1101/2020.04.07.028167.

23. Zhang, F.; Abudayyeh, O.O.; Gootenberg, J.S.; Sciences, C.; Mathers, L. A protocol for detection of COVID-19 using CRISPR diagnostics. *Bioarchive.* **2020**, 1–8.

24. Ding, X.; Yin, K.; Li, Z.; Liu, C. All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and Visual Detection of Novel Coronavirus SARS-CoV-2 and HIV virus. *bioRxiv.* **2020**, 2020.03.19.998724, doi:10.1101/2020.03.19.998724.

25. Nguyen, L.T.; Smith, B.M.; Jain, P.K. Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection. *bioRxiv.* **2020**, 2020.04.13.036079, doi:10.1101/2020.04.13.036079.

26. Gootenberg, J.S.; Abudayyeh, O.O.; Lee, J.W.; Essletzbichler, P.; Dy, A.J.; Joung, J.; Verdine, V.; Donghia, N.; Daringer, N.M.; Freije, C.A.; et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science.* **2017**, *356*, 438–442, doi:10.1126/science.aam9321.

27. Myhrvold, C.; Freije, C.A.; Gootenberg, J.S.; Abudayyeh, O.O.; Metsky, H.C.; Durbin, A.F.; Kellner, M.J.; Tan, A.L.; Paul, L.M.; Parham, L.A.; et al. Field-deployable viral diagnostics using CRISPR-Cas13. *Science.* **2018**, *360*, 444–448, doi:10.1126/science.aas8836.

28. Chen, J.S.; Ma, E.; Harrington, L.B.; Da Costa, M.; Tian, X.; Palefsky, J.M.; Doudna, J.A. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science.* **2018**, *360*, 436–439, doi:10.1126/science.aar6245.

29. Knott, G.J.; Doudna, J.A. CRISPR-Cas guides the future of genetic engineering. *Science.* **2018**, *361*, 866–869, doi:10.1126/science.aat5011.